q2 adjusted earnings per share $0.91 excluding items.
for q3, broader macro factors impacting business are not anticipated to change dramatically from q2.
expect accelerated improvement toward end of year.
expects ongoing steady demand for elastomer components for injection devices in q3.
aptargroup - strong custom tooling sales reported in q3 2020 by pharma segment's active material science solutions division is not expected to repeat.
will look to implement further price adjustments as necessary to pass inflation and cost pressures over time.
sees q3 earnings per share $0.90 to $0.98 excluding items.
